华仁药业股份有限公司 2018 年第一季度报告全文 华仁药业股份有限公司 2018-055 2018 年 04 月 1 华仁药业股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周强、主管会计工作负责人王文萍及会计机构负责人(会计主管 人员)周娜声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 2018 年第一季度报告 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 323,059,506.48 | 270,958,410.16 | 19.23% | | 归属于上市公司股东的净利润（元） | 2,265,926.44 | 4,150,88 ...

Financial Performance - The company reported a significant increase in revenue, with total revenue reaching 1.2 billion RMB, representing a year-on-year growth of 15%[5]. - The company's operating revenue for 2017 was CNY 1,311,875,365.87, representing a 5.04% increase from CNY 1,248,972,198.38 in 2016[19]. - Net profit attributable to shareholders for 2017 was CNY 37,535,035.37, a significant increase of 56.75% compared to CNY 23,946,244.71 in 2016[19]. - The net profit after deducting non-recurring gains and losses was CNY 43,505,027.09, up 52.35% from CNY 28,555,991.29 in 2016[19]. - The net cash flow from operating activities increased by 16.20% to CNY 211,080,360.47 from CNY 181,650,110.18 in 2016[19]. - The total assets at the end of 2017 were CNY 2,887,101,982.52, reflecting a 5.95% increase from CNY 2,724,915,464.19 at the end of 2016[19]. - The basic earnings per share for 2017 were CNY 0.0396, a 74.45% increase from CNY 0.0227 in 2016[19]. - The weighted average return on equity for 2017 was 2.54%, up from 1.62% in 2016[19]. - The company achieved total operating revenue of 1.31 billion yuan, a year-on-year increase of 5.04%[44]. - The net profit attributable to shareholders reached 37.54 million yuan, reflecting a significant year-on-year growth of 56.75%[44]. Dividend Distribution - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares, with a total of 986,105,137 shares as the base for the distribution[6]. - In 2017, the company distributed cash dividends of 0.2 RMB per share, totaling approximately 19.72 million RMB, representing 100% of the profit distribution[109]. - In 2017, the cash dividend amount was 19,722,102.74, representing 52.54% of the net profit attributable to ordinary shareholders of 37,535,035.37[112]. - In 2016, the cash dividend amount was 16,753,285.40, which accounted for 69.96% of the net profit attributable to ordinary shareholders of 23,946,244.71[112]. - The company did not propose a cash dividend distribution plan for the reporting period despite having positive distributable profits for ordinary shareholders[112]. Market and Product Development - The company is actively exploring new growth areas in health care services, aiming to enhance its core competitiveness and develop future profit points[5]. - The company plans to expand its product line through joint ventures and collaborations to enhance profitability[29]. - The company has introduced new product lines, including agent sales of indwelling needle products, to enrich its product structure[45]. - The company has initiated a comprehensive reform in R&D management, focusing on blood purification-related products and accelerating development progress[47]. - The company is committed to improving product quality through enhanced quality management systems and ensuring compliance with GMP standards[101]. - The company plans to focus on key product development and sales, with significant technology and intellectual property transfers to enhance market position[56]. - The company aims to explore investment opportunities across the entire healthcare industry chain, including preventive healthcare, diagnosis, treatment, and medical services[94]. Operational Efficiency and Cost Management - The accounts receivable balance was notably high, occupying a substantial amount of capital, which led to a focus on customer classification management to improve asset utilization efficiency[6]. - Rising raw material costs due to stricter production standards and environmental regulations have increased cost control challenges for the company[6]. - The company is focusing on developing new suppliers and signing comprehensive contracts to stabilize procurement costs amid rising production costs[6]. - The company is committed to enhancing its production efficiency and resource scheduling capabilities through the integration of information technology and supply chain management[6]. - The company aims to improve its asset turnover rate and overall operational efficiency through rigorous credit management policies and prioritizing resource allocation to high-quality customers[6]. - The company has established a unified management platform across finance, procurement, human resources, and IT departments to enhance efficiency and reduce costs[30]. Risks and Challenges - The company faces risks from industry policies, including drug price reductions and stricter regulations, which may increase market competition[5]. - The company anticipates increased pressure from regulatory and market environments, leading to higher industry entry barriers and accelerated industry consolidation[93]. Corporate Governance and Compliance - The actual controller and shareholders made commitments to avoid competition with Huaren Pharmaceutical's main business, ensuring no direct or indirect competition[113]. - The commitments included maintaining independent operations and financial management, ensuring the company has independent assets and financial systems[114]. - The company guarantees independent decision-making and compliance with legal tax obligations[114]. - The company has established a complete independent organizational structure and governance system[114]. - The reporting period confirmed that all commitments were fulfilled as of the end of the reporting period[113]. - The company has maintained a good integrity status, with no violations reported by controlling shareholders or actual controllers[125]. Research and Development - The company focused on five ongoing R&D projects in the blood purification field, aiming to enhance competitiveness[77]. - The company has a strategic focus on enhancing the training of middle and senior management to improve decision-making and management capabilities[189]. - The company has implemented a performance management system where 60% of the salary is paid monthly without assessment, and the remaining 40% is based on quarterly and annual performance[187]. Employee and Management Information - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 471.07 million yuan[181]. - The company has a total of 60 employees with a master's degree or above, and 562 with a bachelor's degree[186]. - The company has a total of 2,639 employees, with 1,515 in the parent company and 1,124 in major subsidiaries[185]. - The average age of the board members is approximately 43 years, with a mix of genders represented[181]. - The company has a diverse board with members holding various positions in other organizations[181]. Subsidiaries and Joint Ventures - The company has established several new subsidiaries, including Qingdao Huarun Medical Valley Entrepreneurship Service Co., Ltd. and Guangzhou Huarun Medical Investment Co., Ltd., expanding its operational footprint[70][71]. - The company has established a joint venture with Shandong Nuoan Nuotai Information Technology Co., Ltd. to promote the construction of a kidney disease medical alliance hierarchical diagnosis and treatment management service platform[53]. - The company has established a joint venture, Shandong Yilian Huitong Medical Technology Co., Ltd., with an investment of 10.2 million RMB, focusing on the development and promotion of kidney disease products[147]. - Another joint venture, Guangzhou Huiren Medical Investment Co., Ltd., was established with an investment of 25.5 million RMB to enhance the company's medical investment platform[147].

Financial Performance - Net profit attributable to shareholders rose by 33.74% to CNY 14,693,100.86 for the current period[9] - Operating revenue for the current period was CNY 327,854,241.98, reflecting a slight increase of 0.33% year-on-year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 39.13% to CNY 17,623,474.35[9] - Basic earnings per share increased by 34.23% to CNY 0.0149 for the current period[9] - Total profit increased by 123.30% year-on-year, driven by enhanced market expansion efforts and an increase in the proportion of industrial revenue, leading to a rise in overall gross margin[18] - Net profit for Q3 2017 was CNY 15.38 million, up from CNY 10.82 million, reflecting a growth of 42.5% year-over-year[44] - The net profit attributable to shareholders of the parent company was CNY 14.69 million, compared to CNY 10.99 million in the previous year, an increase of 33.5%[44] - Total operating revenue for the current period reached ¥914,205,017.97, a slight increase from ¥909,018,078.33 in the previous period, representing a growth of approximately 0.2%[50] - Net profit for the current period was ¥24,554,835.06, compared to ¥12,701,444.48 in the previous period, indicating a significant increase of approximately 93.4%[52] - The company reported a total profit of ¥32,576,712.18, up from ¥14,588,644.41, which is an increase of around 122.3%[52] Assets and Liabilities - Total assets increased by 3.95% to CNY 2,832,670,800.09 compared to the end of the previous year[9] - Cash and cash equivalents increased by 440.73% compared to the beginning of the period, mainly due to reduced cash procurement payments after internal supply chain integration and increased net cash flow from operating activities[17] - Long-term borrowings increased by 129.73% compared to the beginning of the period, primarily due to the addition of an 80 million yuan long-term mortgage loan[17] - The company's total liabilities increased to RMB 1,292,077,206.63 from RMB 1,199,015,654.42, reflecting a growth of approximately 7.8%[37] - The equity attributable to the parent company reached RMB 1,477,969,137.34, slightly up from RMB 1,464,671,074.11, showing a marginal increase[38] Cash Flow - Cash flow from operating activities for the year-to-date reached CNY 165,909,092.11, up by 58.95%[9] - Net cash flow from operating activities increased by 58.95% year-on-year, attributed to reduced cash procurement payments following internal supply chain integration[18] - The cash inflow from operating activities totaled ¥923,437,177.17, a slight decrease of 0.5% compared to ¥928,887,012.91 in the previous period[59] - The net cash flow from operating activities increased to ¥165,909,092.11, up 58.8% from ¥104,378,344.37 in the previous period[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,360[13] - The top ten shareholders held a combined 61.63% of the shares, with Guangdong Yongyu Hengfeng Investment Co., Ltd. holding the largest share at 16.76%[13] - The company implemented a cash dividend policy, distributing RMB 0.15 per 10 shares to shareholders, totaling RMB 6,902,735.96 for the 2016 profits[29] - The company plans to continue its cash dividend distribution based on the profits from 2016, ensuring no excess distribution occurs[29] Market and Strategic Initiatives - The company is focusing on enhancing its product development and market expansion strategies to drive future growth[44] - The company plans to continue investing in research and development to innovate new products and technologies[44] - The company has submitted a share placement application to the China Securities Regulatory Commission and received acceptance on August 21, 2017[22] - The company established a joint venture with Qingdao Huarentang Medical Management Co., Ltd. and Shandong Nuonant Technology Co., Ltd. on September 22, 2017[20] Compliance and Governance - The company reported a commitment to avoid any competition with its subsidiaries and other controlled enterprises, ensuring no direct or indirect engagement in competing businesses[26] - The commitment letter from the actual controller of the company remains effective and irrevocable during the period of shareholding, terminating only after two years of no shareholding[27] - The company has obtained a direct sales operating license for health food products, ensuring that controlled enterprises will not engage in similar business activities[28] - The company has made a promise to cease any competitive activities if any potential competition arises due to changes in national policies or business integration[28] - The company has committed to ensuring that any competing business will be either integrated into its operations or transferred to unrelated third parties[28] - The company has stated that it will bear legal responsibilities for any losses incurred by the company or its subsidiaries due to violations of the commitments made[28] - The company has confirmed that there are no related transactions that could harm its independence during the control period[26] - The company has reiterated its commitment to maintaining the integrity of its operations and protecting shareholder interests[27] - The company has established a clear framework for handling potential conflicts of interest and competition with its subsidiaries[26] - The company has emphasized the importance of compliance with its commitments to avoid any economic losses to itself or its shareholders[27]

Financial Performance - Total revenue for the reporting period was CNY 586,350,775.99, a year-on-year increase of 0.71%[24]. - Net profit attributable to shareholders was CNY 8,466,013.74, representing a significant increase of 176.55% compared to the same period last year[24]. - Net profit after deducting non-recurring gains and losses was CNY 8,266,478.18, up 94.28% year-on-year[24]. - Net cash flow from operating activities reached CNY 176,646,541.95, a remarkable increase of 772.20% compared to the previous year[24]. - The total profit for the same period was CNY 13,231,729.09, representing a significant year-on-year growth of 742.51%[49]. - Basic earnings per share rose to CNY 0.0086, an increase of 82.98% compared to the previous year[24]. - The total comprehensive income for the period reached ¥8,831,782.86, compared to ¥1,442,910.72 in the previous period[156]. - The total comprehensive income for the current period is 8,466,013.74, with a decrease of 9,861,051.37 compared to the previous period[165]. Cash Flow and Liquidity - Cash and cash equivalents increased by 371.78% compared to the beginning of the period, attributed to improved cash collection and reduced cash payments for materials and expenses[63]. - The company's cash flow from operating activities increased by 772.20% to $176.65 million, attributed to lower cash procurement and expenses[66]. - The net increase in cash and cash equivalents was $112.13 million, a 324.60% increase compared to the previous year[66]. - The company reported a significant balance of accounts receivable at 619.75 million RMB, which poses liquidity risks and may lead to potential bad debt losses[80]. - The company is implementing comprehensive credit management processes to monitor and accelerate accounts receivable collection[80]. Market Strategy and Product Development - The company focuses on high-end infusion products, primarily selling dual-chamber dual-valve infusion products, and aims to expand its market share through differentiated sales strategies and product upgrades[7]. - The company is actively exploring opportunities in the medical services sector to enhance its core competitiveness and develop future profit points[9]. - The company is committed to expanding its market presence and enhancing its product structure through continuous sales reforms and marketing strategies[39]. - The company is leveraging existing channel advantages to introduce new products and expand its business, aiming to improve profitability[79]. - The company is enhancing its product structure and innovating sales models to improve asset turnover and core competitiveness in response to market changes[80]. Risks and Challenges - The company faces risks from intense market competition in the large-volume injection segment, with competitors expanding capacity and upgrading technology[7]. - The company faces risks from industry policy changes, including reforms in the medical and healthcare system, which may impact the demand for large-volume infusion products[80]. - The company is committed to capturing development opportunities arising from market changes while managing associated risks effectively[80]. Shareholder and Governance Matters - The company has established a commitment to avoid related party transactions, ensuring fair and transparent dealings[87]. - The company guarantees that its financial personnel will work independently and not engage in other paid positions[86]. - The actual controller of Huaren Pharmaceutical, Zhou Xijian, committed to avoiding and resolving competition issues during his control period[85]. - There are no current competitive conflicts between the company and its controlling entities, with a commitment to avoid any future competition[88]. - The company did not experience any changes in its controlling shareholder during the reporting period[127]. Environmental and Compliance - The company’s environmental protection facilities operated normally, ensuring that wastewater and waste gas emissions met environmental standards[112]. - The financial statements were prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring compliance and accuracy[181]. - The company maintains a continuous operating capability for at least 12 months from the reporting date[182]. Research and Development - The company emphasizes research and development of new pharmaceutical packaging materials and medical devices[177]. - The company has accelerated the R&D of peritoneal dialysis products and achieved new progress in the development of other related products[57]. Share Capital and Equity - The company plans to distribute a cash dividend of 0.07 yuan per 10 shares based on a total share capital of 986,105,137 shares, amounting to a total distribution of approximately 6.90 million yuan[12]. - The company plans to issue up to 197,221,027 shares at a ratio of no more than 2 shares for every 10 shares held, aiming to raise a total of 703 million yuan[61]. - The total number of shareholders at the end of the reporting period is 26,041[125].

华仁药业股份有限公司 2017 年第一季度报告全文 华仁药业股份有限公司 2017 年第一季度报告 2017-026 2017 年 04 月 1 华仁药业股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周强、主管会计工作负责人王文萍及会计机构负责人(会计主管 人员)周娜声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 270,958,410.16 | 276,136,950.69 | -1.88% | | 归属于上市公司股东的净利润（元） | 4,150,882 ...

华仁药业股份有限公司 2016 年年度报告全文 华仁药业股份有限公司 2016 年年度报告 2017-022 2017 年 03 月 1 华仁药业股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人周强、主管会计工作负责人王文萍及会计机构负责人(会计主管 人员)周娜声明：保证年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 | | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | --- | | 姚立 | | 独立董事 | 工作原因 | 徐胜锐 | 公司在本报告中"九、公司未来发展的展望"部分描述了公司经营中可能存 在的风险及应对措施，敬请投资者注意并仔细阅读。 公司经本次董事会审议通过的利润分配预案为：以 657,403,425 股为基数， 向全体股东每 10 股派发现金红利 0.15 元（ ...

华仁药业股份有限公司 2016 年第三季度报告全文 华仁药业股份有限公司 2016 年第三季度报告 2016-109 2016 年 10 月 1 华仁药业股份有限公司 2016 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周强、主管会计工作负责人王文萍及会计机构负责人(会计主管 人员)周娜声明：保证季度报告中财务报告的真实、完整。 2 华仁药业股份有限公司 2016 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 除上述各项之外的其他营业外收入和支出 | -3,386,791.01 | | | 减：所得税影响额 | -512,359.29 | | | 合计 | -2,874,431.72 | -- | 公司是否因会计政策变更及会计差错更正等追溯调整 ...

华仁药业股份有限公司 2016 年第一季度报告 2016-051 2016 年 04 月 1 华仁药业股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)王文萍声明：保证季度报告中财务报告的真实、完整。 华仁药业股份有限公司 2016 年第一季度报告全文 2 华仁药业股份有限公司 2016 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 276,136,950.69 | 242,424,553.17 | 13.91% | | 归属于上市公司股东的净利润（元） | 2, ...

华仁药业股份有限公司 2015 年年度报告全文 华仁药业股份有限公司 2015 年年度报告 2016-042 2016 年 04 月 1 华仁药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主管人员)王文萍声明：保证 年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 梁福东 | 董事 | 工作原因 | 褚旭 | 1、 行业政策风险 随着医药卫生体制改革的不断推进，国家陆续出台一系列改革政策，这对医药行业既是挑战也是机遇。 对此，公司 2016 年将围绕"调整思路 创新模式"展开各项工作，努力捕捉市场变化带来的发展机遇。一方 面，不断健全产品结构，创新销售模式，提高资产周转率。另 ...

2015 年第三季度报告 2015-110 2015 年 10 月 1 华仁药业股份有限公司 2015 年第三季度报告全文 华仁药业股份有限公司 2015 年第三季度报告全文 华仁药业股份有限公司 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主管人员)王文萍声明：保证 季度报告中财务报告的真实、完整。 2 华仁药业股份有限公司 2015 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,611,029,775.16 | | 2,621,597,844.63 | -0.40% ...